<DOC>
	<DOCNO>NCT00635531</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability , pharmacokinetics alprazolam extend release ( XR ) treatment adolescent panic disorder</brief_summary>
	<brief_title>A Study Evaluate Use Extended Release Alprazolam Treatment Adolescents With Panic Disorder</brief_title>
	<detailed_description>Due recruitment difficulty adolescent population , clinical program alprazolam XR cancel study terminate 1 September 2004 . There safety concern lead decision .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>A primary DSMIVTR diagnosis panic disorder without agoraphobia base Mini International Neuropsychiatric Interview Children Adolescents At least average one 4symptom panic attack per week last 4 week prior screen At least average one 4symptom panic attack per week last 4 week prior baseline At least one 4symptom panic attack 7 day prior baseline Current ( past 6 month ) DSMIVTR diagnosis obsessive compulsive disorder , major depressive disorder , dysthymic disorder , alcohol and/or substance dependence Primary DSMIVTR diagnosis social anxiety disorder , posttraumatic stress disorder , simple phobia , separation anxiety disorder , generalize anxiety disorder , conduct disorder , oppositional defiant disorder , attention deficit hyperactivity disorder Any current past history schizophrenia psychosis ; bipolar disorder cyclothymia ; dementia , delirium organic brain disease ; Axis I eat disorder ; mental retardation , Asperger 's disorder , serious developmental disorder A CDRSR score &gt; 35</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>